Home » Stocks » GWPH

GW Pharmaceuticals PLC (GWPH)

Stock Price: $218.40 USD -0.13 (-0.06%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 6.53B
Revenue (ttm) 527.21M
Net Income (ttm) -58.13M
Shares Out 31.53M
EPS (ttm) -1.86
PE Ratio n/a
Forward PE 833.33
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $218.40
Previous Close $218.53
Change ($) -0.13
Change (%) -0.06%
Day's Open 218.55
Day's Range 218.27 - 218.78
Day's Volume 463,005
52-Week Range 87.07 - 219.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Marijuana stocks may still have some roadblocks until the U.S. market opens, but change is coming, and medical marijuana is leading the way. The post 7 Medical Marijuana Stocks For Your Waiting Room app...

Other stocks mentioned: CGC, CRLBF, CRON, CURLF, HEXO, IIPR
8 hours ago - InvestorPlace

GW Pharmaceuticals PLC (NASDAQ:GWPH), the medicinal cannabis giant, has received European Commission (EC) approval for the treatment of seizures associated with tuberous sclerosis complex. The EC has ap...

11 hours ago - Proactive Investors

– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –

15 hours ago - GlobeNewsWire

– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe –

15 hours ago - GlobeNewsWire

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies

1 week ago - GlobeNewsWire

2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.

Other stocks mentioned: GRWG, GTBIF, JAZZ
1 week ago - The Motley Fool

Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.

Other stocks mentioned: JAZZ
1 week ago - The Motley Fool

Could these areas see more gains ahead?

Other stocks mentioned: APHA, BTI, FRO, JAZZ, MJ, NAT, OGI ...
1 week ago - The Motley Fool

We highlight top performing ETF areas of the first quarter

Other stocks mentioned: APHA, BDRY, BLOK, CNBS, MJ, MSTR, NVDA ...
2 weeks ago - Zacks Investment Research

Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.

Other stocks mentioned: JAZZ
2 weeks ago - The Motley Fool

Multiple high-profile companies may still be on the hunt for a deal.

Other stocks mentioned: ACB, APHA, BTI, JAZZ, OGI, SNDL, TLRY
3 weeks ago - The Motley Fool

The stock of GW Pharmaceuticals PLC (NAS:GWPH, 30-year Financials) gives every indication of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate o...

4 weeks ago - GuruFocus

These are the top players in the expanding $19.6 billion U.S. marijuana market.

Other stocks mentioned: JAZZ, JUSHF
1 month ago - The Motley Fool

The cannabis-based pharmaceutical company agreed to be acquired.

1 month ago - The Motley Fool

Each of these cannabis stocks blazed higher by between 20% and 208% last month.

Other stocks mentioned: APHA, CURLF, JAZZ, MMNFF, OGI, SNDL, TLRY
1 month ago - The Motley Fool

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for GW Pharmaceuticals Plc's (NASDAQ: GWPH) Epidyolex (cannabidiol). It is an a...

1 month ago - Benzinga

– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – – If approved by the European Commission (EC), the label for EPIDYOLEX® will...

1 month ago - GlobeNewsWire

– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – – If approved by the European Commission (EC), the label for EPIDYOLEX® will...

1 month ago - GlobeNewsWire

This month, two groundbreaking deals in cannabis were announced — the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals and the combination of the multi-state operator (MSO) Parallel with the sp...

1 month ago - Benzinga

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will cont...

Other stocks mentioned: ARNA, CGC, HEXO, NBEV, SNDL, TLRY, YCBD
2 months ago - Schaeffers Research

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Other stocks mentioned: APHA, CGC, CNBS, JAZZ, MJ, POTX, THCX ...
2 months ago - Zacks Investment Research

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...

Other stocks mentioned: JAZZ, OILFF
2 months ago - Proactive Investors

The company's net loss was far narrower than many expected.

2 months ago - The Motley Fool

Interest in cannabis stocks has sparked into life this month as London welcomed its first two specialist medical marijuana companies. A surge in share prices was seen around the world last week, as the ...

2 months ago - Proactive Investors

Shares of GW Pharmaceuticals (NASDAQ:GWPH) fell 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 14.29% year over year to ($0.08), which b...

2 months ago - Benzinga

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –

2 months ago - GlobeNewsWire

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Act...

2 months ago - PRNewsWire

The sector is hot again on the heels of two large deals.

Other stocks mentioned: ACB, ACRGF, APHA, CGC, CRON, CURLF, JAZZ ...
2 months ago - The Motley Fool

Cannabis stocks seem poised to gain on hopes of removal of the federal ban on cannabis products under the new administration.

Other stocks mentioned: APHA, CGC, JAZZ, OGI, TLRY
2 months ago - Zacks Investment Research

Few investors saw this one coming.

2 months ago - The Motley Fool

A blockbuster deal announced earlier this week could be a sign of a bright future for cannabidiol-oriented pharmaceutical companies. On Wednesday, cancer therapy developer Jazz Pharmaceuticals PLC (NASD...

Other stocks mentioned: JAZZ
2 months ago - Proactive Investors

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) recently-announced deal to acquire cannabis-derived drug maker GW Pharmaceuticals plc (NASDAQ:GWPH) for US$7.2 billion in cash and stock has boosted investor int...

Other stocks mentioned: JAZZ
2 months ago - Proactive Investors

Jazz is paying $7.2 million to buy the maker of CBD-derived drug Epidiolex. Is it a smart deal?

Other stocks mentioned: JAZZ
2 months ago - The Motley Fool

Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will deve...

Other stocks mentioned: ARNA, GNLN, GRWG, JAZZ, OGI, SNDL, TLRY ...
2 months ago - Schaeffers Research

Marijuana stocks are soaring higher on a string of Democratic electoral wins. But not every company in this troubled sector is a winner.

Other stocks mentioned: APHA, OGI
2 months ago - InvestorPlace

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

2 months ago - Zacks Investment Research

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: GW Pharmaceuticals plc (NASDAQ: GWPH) concerning potent...

2 months ago - PRNewsWire

WILMINGTON, Del., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GW Pharmaceuticals plc (“GW Pharmaceuticals”) (NASDAQ GM: GWPH) regarding possible breaches of ...

2 months ago - GlobeNewsWire

Jazz Pharmaceuticals has agreed to acquire GW Pharmaceuticals, maker of the first epilepsy drug derived from marijuana, for $7.2 billion in cash and stock.

2 months ago - Investopedia

NEW YORK, Feb. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc ("GWPH" or the "C...

2 months ago - PRNewsWire

The deal to buy GW Pharmaceuticals creates a leader in neuroscience.

Other stocks mentioned: JAZZ
2 months ago - The Motley Fool

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether GW Pharmaceuticals plc (NASDAQ: GWPH) and its board of directors violated the federal securities ...

2 months ago - Business Wire

In a quiet market, marijuana companies stood out.

Other stocks mentioned: ACB, APHA, CGC, CRON, JAZZ, TLRY
2 months ago - The Motley Fool

NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of GW Pharmaceu...

2 months ago - GlobeNewsWire

GW Pharmaceuticals (GWPH) stock is soaring higher on Wednesday following news that Jazz Pharmaceuticals (JAZZ) is acquiring the company. The post GWPH Stock: 12 Things to Know About the GW Pharma-Jazz P...

Other stocks mentioned: JAZZ
2 months ago - InvestorPlace

Marijuana stocks rallied as Jazz Pharmaceuticals said it would buy GW Pharma. GWPH stock jumped.

Other stocks mentioned: JAZZ
2 months ago - Investors Business Daily

Jazz Pharmaceuticals Plc said on Wednesday it would buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding a cannabis-based epilepsy treatment.

Other stocks mentioned: JAZZ
2 months ago - Reuters

Investors cheered an unexpected acquisition of the cannabinoid-focused biotech.

2 months ago - The Motley Fool

Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 billion

YouTube video

Jazz Pharmaceuticals said on Wednesday it would buy GW Pharmaceuticals in a $7.2 billion cash-and-stock deal to bolster its neuroscience business by adding cannabis-based epilepsy treatment. CNBC's Jim ...

Other stocks mentioned: JAZZ
2 months ago - CNBC Television

Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share (...

Other stocks mentioned: JAZZ
2 months ago - 24/7 Wall Street

About GWPH

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of s... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
May 1, 2013
CEO
Justin Gover
Employees
1,161
Stock Exchange
NASDAQ
Ticker Symbol
GWPH
Full Company Profile

Financial Performance

In 2020, GWPH's revenue was $527.21 million, an increase of 69.34% compared to the previous year's $311.33 million. Losses were -$58.13 million, 544.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for GWPH stock is "Buy." The 12-month stock price forecast is 204.90, which is a decrease of -6.18% from the latest price.

Price Target
$204.90
(-6.18% downside)
Analyst Consensus: Buy